Department of Infectious Diseases, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Service, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
J Med Primatol. 2022 Oct;51(5):278-283. doi: 10.1111/jmp.12613. Epub 2022 Aug 27.
One strategy to eliminate latently infected cells that persist in people with HIV on antiretroviral therapy is to activate virus transcription and virus production to induce virus or immune-mediated cell death. This is called latency reversal. Despite clear activity of multiple latency reversal agents in vitro, clinical trials of latency-reversing agents have not shown significant reduction in latently infected cells. We review new insights into the biology of HIV latency and discuss novel approaches to enhance the efficacy of latency reversal agents.
一种消除接受抗逆转录病毒疗法的 HIV 感染者体内潜伏感染细胞的策略是激活病毒转录和病毒产生,从而诱导病毒或免疫介导的细胞死亡。这被称为潜伏期逆转。尽管体外有多种潜伏期逆转剂具有明显的活性,但潜伏期逆转剂的临床试验并未显示潜伏感染细胞的显著减少。我们综述了 HIV 潜伏生物学的新见解,并讨论了增强潜伏期逆转剂疗效的新方法。